Prasugrel Monotherapy Following PrImary Percutaneous Coronary Interventionfor ST-elevation Myocardial Infarctio
Phase 4
Recruiting
- Conditions
- ST-Elevation Myocardial Infarction
- Registration Number
- JPRN-jRCTs052220145
- Lead Sponsor
- akazawa Gaku
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2258
Inclusion Criteria
Patients scheduled for Primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGY)
STEMI patients
Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months
Exclusion Criteria
Patients taking anticoagulants
Under 18 years old
Prognosis less than 1 year
Participated in other intervention studies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the composite primary cardiovascular endpoint consisting of all-cause death/myocardial infarction/stroke at 12 months after stent implantation
- Secondary Outcome Measures
Name Time Method The major secondary endpoint of this study is as follows:<br> 12 months after enrollment<br> Major bleeding (BARC 3 or 5 bleeding)<br><br>The secondary endpoints of this study are as follows: They will be assessed at 12 months after enrollment.<br> All-cause death<br> Cardiovascular death<br> Non-cardiovascular death<br> MI (target-vessel, non-target vessel)<br> Stroke<br> Ischemic stroke<br> Hemorrhagic stroke<br> ST (ARC)<br> TLF<br> TVF<br> POCE<br> Any TLR<br> Clinically driven TLR<br> Non TLR<br> CABG<br> Any TVR<br> Any coronary revascularization<br> Bleeding complications<br> BARC 2<br> BARC 3<br> BARC 4<br> BARC 5<br> BARC 2/3/5<br> TIMI major<br> TIMI minor<br> TIMI major/minor<br> GUSTO severe<br> GUSTO moderate<br> GUSTO moderate/severe<br> Intracranial bleeding<br> Gastrointestinal bleeding<br> Gastrointestinal complaints